CoChat

Targeted CNS delivery using human MiniPromoters and demonstrated compatibility with adeno-associated viral vectors

Open access
de Leeuw, Charles N, Dyka, Frank M, Boye, Sanford L, Laprise, Stéphanie, Zhou, Michelle, Chou, Alice Y, Borretta, Lisa, McInerny, Simone C, Banks, Kathleen G, Portales-Casamar, Elodie, Swanson, Magdalena I, D'Souza, Cletus A, Boye, Shannon E, Jones, Steven JM, Holt, Robert A, Goldowitz, Daniel, Hauswirth, William W, Wasserman, Wyeth W, Simpson, Elizabeth M · 2014 · Molecular Therapy - Methods & Clinical Development
Cited by 58

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Critical for human gene therapy is the availability of small promoters tools to drive gene expression in a highly specific and reproducible manner. We tackled this challenge by developing human DNA MiniPromoters (MiniPs) using computational biology and phylogenetic conservation. MiniPs were tested in mouse as single-copy knock-ins at the Hprt locus on the X chromosome and evaluated for lacZ reporter expression in central nervous system (CNS) and non–CNS tissue. Eighteen novel MiniPs driving expression in mouse brain were identified, 2 MiniPs for driving pan-neuronal expression and 17 MiniPs for the mouse eye. Key areas of therapeutic interest were represented in this set: the cerebral cortex, embryonic hypothalamus, spinal cord, bipolar and ganglion cells of the retina, and skeletal muscle. We also demonstrated that three retinal ganglion cell MiniPs exhibit similar cell type specificity when delivered via adeno-associated virus vectors intravitreally. We conclude that our methodology and characterization has resulted in desirable expression characteristics that are intrinsic to the MiniPromoter, not dictated by copy-number effects or genomic location, and results in constructs predisposed to success in adeno-associated virus. These MiniPs are immediately applicable for preclinical studies toward gene therapy in humans and are publicly available to facilitate basic and clinical research, and human gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mtm.2013.5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 58

Metadata

Authors
de Leeuw, C. N., Dyka, F. M., Boye, S. L., Laprise, S., Zhou, M., Chou, A. Y., Borretta, L., McInerny, S. C., Banks, K. G., Portales-Casamar, E., Swanson, M. I., D'Souza, C. A., Boye, S. E., Jones, S. J., Holt, R. A., Goldowitz, D., Hauswirth, W. W., Wasserman, W. W., & Simpson, E. M.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2014
Volume
1
Pages
5
ISSN
2329-0501 (ISSN-L)
OpenAlex
W2042183771
Cited by
58
References
17
FWCI
2.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted CNS delivery using human MiniPromoters and demonstrated compatibility with adeno-associated viral vectors. https://app.cochat.ai/papers/10.1038/mtm.2013.5
The paper
de Leeuw, C. N., Dyka, F. M., Boye, S. L., Laprise, S., Zhou, M., Chou, A. Y., Borretta, L., McInerny, S. C., Banks, K. G., Portales-Casamar, E., Swanson, M. I., D'Souza, C. A., Boye, S. E., Jones, S. J., Holt, R. A., Goldowitz, D., Hauswirth, W. W., Wasserman, W. W., & Simpson, E. M. (2014). Targeted CNS delivery using human MiniPromoters and demonstrated compatibility with adeno-associated viral vectors. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1038/mtm.2013.5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.